No Data
No Data
Sector Update: Health Care Stocks Advance Premarket Thursday
Health care stocks were advancing premarket Thursday, with the Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) recently 0.5% higher. Akebia Therapeutics (AKBA
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China
Hutchmed (HCM) said late Wednesday the China National Medical Products Administration has accepted for review its supplemental new drug application for savolitinib as a treatment for adult patients wi
On Wednesday, HUTCHMED Announced Savolitinib SNDA Accepted in China For Treatment-Naïve Or Previously Treated Patients With Locally Advanced Or Metastatic MET Exon 14 NSCLC
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application ("sNDA") for savolitinib, in adult patients with locally advanced or metastat
Do Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?
Hehuang Pharmaceutical (00013.HK): A marketing application for savolitinib (savolitinib) for the treatment of primary treatment and treatment of MET exon 14 non-small cell lung cancer was accepted in China
On March 28, Ge Longhui Pharmaceutical (00013.HK) announced today that the marketing application for new indications of sevotinib for the treatment of locally advanced or metastatic non-small cell lung cancer in adults with locally advanced or metastatic non-small cell lung cancer with the interstitium-epithelial conversion factor (“MET”) exon 14 jump has been accepted by the China Drug Administration (“State Drug Administration”). If approved, the new labeling indication for sevolitinib in China will be extended to cover first-time patients.
Hehuang Pharmaceutical (00013) announced that the marketing application for new indications of sevolitinib has been accepted by the State Drug Administration
Hehuang Pharmaceutical (00013) announced that sevotinib is used to treat interstitial to epithelial conversion factor (MET) exons...
No Data